ABSTRACT Objectives: To evaluate the effects of more intensive smoking cessation interventions compared to less intensive interventions on smoking cessation in people with type 1 or type 2 diabetes.
Setting: Primary, secondary and tertiary care. Participants: Adults with type 1 or type 2 diabetes. Interventions: Smoking cessation interventions or medication (more intensive interventions) compared to usual care, counselling or optional medication (less intensive interventions).
Outcome measures: Biochemically verified smoking cessation was the primary outcome. Secondary outcomes were adverse events and effects on glycaemic control. We also carried out a pooled analysis of self-reported smoking cessation outcomes.
Results: We screened 1783 citations and reviewed seven articles reporting eight trials in 872 participants. All trials were of 6 months duration. Three trials included pharmacotherapy for smoking cessation. The risk ratio of biochemically verified smoking cessation was 1.32 (95% CI 0.23 to 7.43) for the more intensive interventions compared to less intensive interventions with significant heterogeneity (I 2 =76%). Only one trial reported measures of glycaemic control.
Conclusions:
There is an absence of evidence of efficacy for more intensive smoking cessation interventions in people with diabetes. The more intensive strategies tested in trials to date include interventions used in the general population, adding in diabetes-specific education about increased risk. Future research should focus on multicomponent smoking cessation interventions carried out over a period of at least 1 year, and also assess impact on glycaemic control.
INTRODUCTION
For adults with diabetes, as in the wider population, smoking is associated with an increased risk of cardiovascular events and death. A recent systematic review and meta-analysis of prospective studies on diabetes reported that smoking increased the risk of death by 48%, coronary heart disease by 54%, stroke by 44% and myocardial infarction by 52%. 1 The risk for coronary heart disease, stroke and proteinuria is directly related to the number of cigarettes smoked per day. 2 3 Patients with diabetes who smoke have higher glycated haemoglobin (HbA1c) levels 4 and are more likely to experience severe hypoglycaemia. 5 People with diabetes who stop smoking are likely to have a lower risk of death and cardiovascular events compared with those who continue to smoke. 1 Smoking cessation is also associated with a reduction in levels of albuminuria, improvement of glycaemic control and lipid profile. 6 Smoking cessation has been recommended as a routine component of the treatment of diabetes by the American Diabetes Association, 7 although evidence to guide best practice is limited. 8 Strengths and limitations of this study ▪ It is the first systematic review of randomised trials of smoking cessation interventions in diabetes. ▪ The statistical power of our attempts to pool data is limited by the small number of trials published to date and a relatively small number of participants in the published trials. ▪ Interventions offered and groups studied are heterogeneous. ▪ Available evidence to inform treatment strategies for smoking cessation in type 2 diabetes is limited.
People with diabetes are faced with the challenge of extensive changes in their lifestyle, a burden that may be increased by attempts to stop smoking. 9 10 Tailoring smoking cessation programmes to the needs of people with diabetes may lead to improved outcomes compared with usual care, but may also further increase the burden of self-management. Concerns have also been expressed regarding weight gain associated with smoking cessation. 11 We, therefore, carried out a systematic review of randomised controlled trials reporting the effects of smoking cessation interventions in diabetes to inform clinical practice and identify potential for further research to improve patient outcomes.
METHODS

Eligibility criteria
We carried out this systematic review in accordance with the study protocol (see online supplementary appendix 1). 12 Peer-reviewed journal articles and conference abstracts that reported the results of a randomised controlled trial and met the following eligibility criteria were eligible for inclusion: trials recruiting non-pregnant adults with type 1 or type 2 diabetes who smoked at baseline, evaluating pharmacological or nonpharmacological interventions intended to support smoking cessation (more intensive interventions) compared to usual care, counselling or optional medication (less intensive interventions). We included trials reporting at least one of the following outcomes: (1) smoking cessation, (2) glycaemic control, (3) weight. There were no restrictions on length of follow-up or language of publication. We included trials that did not report biochemically verified smoking cessation to fully capture the available evidence, characterise smoking status as reported in these trials and to add to the available data from which we could analyse effects of interventions on glycaemic control and weight where such additional data were available.
Search strategy
We based our search strategy on that used by the Cochrane Tobacco Addiction Group 13 Study selection and data extraction Two reviewers (AN and RB) independently screened the titles and abstracts of identified citations to select those requiring full-text assessment. Where there was disagreement, a third reviewer (AF) assessed the records to reach a consensus. Full-text articles were further assessed and data were entered into a prespecified table including 12 entry fields (see online supplementary appendix 3). The data extraction table included information on: (1) trial methodology, setting and duration of follow-up; (2) population characteristics; (3) type of intervention and (4) analyses and outcomes.
Data reported for intention-to-treat analyses were selected at the longest follow-up point. We assumed a diagnosis of type 1 diabetes in insulin-treated participants if the type of diabetes was not otherwise specified.
Data analysis
We used the Cochrane Collaboration's tool to assess risk of bias at the outcome level. 15 Bias was assessed in duplicate with disagreements resolved by a third reviewer. The assessed domains were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment and completeness of outcome data. Trials deemed to have a high risk of detection bias due to assessing only self-reported smoking cessation were not included in the primary analysis of objectively measured cessation data.
The risk ratio (RR) for biochemically verified smoking cessation with 95% CI was the primary outcome measure in this analysis. We made an a priori decision to use the random effect model to take into account the variability of studied populations and intervention types. The meta-analysis was carried out in Review Manager V.5.2.3 (The Nordic Cochrane Centre, Copenhagen, Denmark) using Mantel-Haenszel method, Cochran's χ 2 test and the I 2 statistic to assess heterogeneity. The main meta-analysis included all measures of biochemically verified smoking cessation outcomes. We also pooled data on self-reported smoking cessation: (1) in all eligible trials and (2) in trials with biochemically verified smoking cessation. We calculated pooled means and SDs and obtained SDs from SEs of the mean using formulas recommended by the Cochrane Collaboration. 16 
RESULTS
A total of 2914 citations were identified (figure 1) from electronic searches. A further 15 relevant publications were identified as citing or cited by included trial reports. After removing duplicates we screened 1783 citations. Based on the title and abstract, 1669 were assessed as ineligible. The full text of the remaining 114 articles was assessed for eligibility. Most were excluded as not reporting a randomised controlled trial (n=43), or included patients who did not have diabetes (n=29) or did not smoke (n=26). One potentially eligible conference abstract could not be retrieved. We contacted the first author, but received no reply. We selected seven articles reporting eight trials for inclusion.
Duration and settings
All eight trials were reported in English and had a 6-month maximum duration of follow-up. Two were reported in a single article. 17 Three trials were carried out in Europe, [18] [19] [20] two in Asia, 21 22 two in Australia 17 and one in North America. 23 
Population
In total, 872 smokers with type 1 or type 2 diabetes participated in the reviewed trials (table 1) . Three trials reported in two publications 17 21 did not include information on the type of diabetes. Two trials 21 22 included only men.
Intervention
Five trials assessed either non-pharmacological interventions to support smoking cessation 17 19 21 or referral to a smoking cessation clinic. 22 Interventions reported in three other trials included optional nicotine replacement therapy (NRT) without bupropion 18 20 or with bupropion. 23 The intervention was delivered by nursing staff or allied health professionals in three trials 18 20 23 and by both doctors and nursing staff or allied health professionals in two trials. 19 21 In one trial, the intervention included advice from a doctor and referral to cessation clinic. 22 In two other trials, intervention delivery was not specified. 17 The interventions were not specifically tailored for people with diabetes apart from the inclusion of educational components focusing on the effects of smoking on the complications of diabetes and glycaemic control.
We did not identify any trials that specifically assessed pharmacological interventions, although among the three identified ongoing trials not included in this review, one European trial assesses the efficacy and safety of smoking cessation with varenicline tartrate in patients with diabetes. 24 The two other ongoing trials carried out in North America 25 and Asia 26 assess the effectiveness of behavioural interventions.
The less intensive intervention comparator groups received usual care, involving advice to stop smoking in three trials, 20 22 23 counselling about general health risks of smoking in another three trials 17 21 22 and diabetesspecific counselling in one trial. 17 In one trial, optional NRT was reported as used in addition to counselling in the comparator group. 18 Outcomes Four of eight trials included a definition of the primary outcome (table 2) . In four trials, smoking cessation was biochemically verified using concentration of breath carbon monoxide (CO), 19 urinary cotinine 19 20 or salivary cotinine. 23 Two trials assessed only self-reported cessation, 21 22 and two trials reported only a total number of people with biochemically verified cessation in the study population. 17 All trials measured smoking cessation as point prevalence abstinence.
Risk of bias
All trials were deemed to have low risk of attrition bias and most trials were assessed as having low risk of detection bias (figure 2, see online supplementary appendix 4). Most trials provided incomplete information on random sequence generation, allocation concealment and blinding of participants and personnel.
Primary outcome
Trial findings are summarised in table 2. One article reporting two trials included only the overall number of patients who stopped smoking in both trials. 17 Two trials 21 22 were excluded from pooled analysis due to high risk of detection bias as a consequence of selfreported cessation outcomes.
Pooled data from the four trials 18-20 23 that reported point prevalence of biochemically verified smoking cessation in both trial arms are summarised in figure 3. For 543 participants, 44 smoking cessation events are reported. The likelihood of biochemically verified smoking cessation was 32% higher in patients who received more intensive intervention compared with less intensive intervention, although this effect was not significant (RR 1.32, 95% CI 0.23 to 7.43).
There was substantial heterogeneity between the results of trials included in the pooled analysis of the primary outcome (χ 2 test for heterogeneity, p=0.006; I 2 =76%). Two trials, 18 19 jointly accounting for 44% of the weight of these results, reported point estimates of effects that suggested a greater likelihood of smoking cessation in the less intensive intervention group compared with the more intensive intervention group. In one trial, 19 the only biochemically verified incident of smoking cessation was recorded in a less intensive intervention group patient who stopped smoking after sustaining a myocardial infarction.
In the pooled analyses of self-reported smoking cessation outcomes in (1) all eligible trials and (2) in trials also reporting biochemically verified smoking cessation, participants allocated to more intensive intervention had, respectively, 1.85 times (RR 1.85, 95% CI 0.81 to 4.22) or 1.39 times (RR 1.39, 95% CI 0.28 to 6.92) greater likelihood of cessation compared with patients allocated to the less intensive intervention.
Secondary outcomes
Other outcomes reported related to smoking outcomes and metabolic outcomes (table 2). Continuous measures of urinary cotinine-creatinine ratio and breath CO were reported for one trial, 19 but the results were not compared between allocated trial groups. In one trial, 23 proportions of patients with HbA1c <7% (53 mmol/mol) in more intensive and less intensive intervention groups were reported at 6 months (61% vs 75%), but were not significantly different ( p=0.16). No trials reported other objectively measured short-term or long-term cardiovascular risk or safety data.
DISCUSSION
Despite an excess cardiovascular risk in people with diabetes, we have identified only a small number of trials evaluating the effect of smoking cessation interventions in this group. Interventions tested in the trials were similar to those used in the general population and included counselling, referral and advice, with, for some, the addition of diabetes-specific education. Interventions and comparator groups were heterogeneous and the pooled results did not provide evidence of efficacy for smoking cessation interventions in people with diabetes. Only one trial reported data on glycaemic outcomes, which were not significantly different between intervention groups. This is, to our knowledge, the first systematic review of randomised trials of smoking cessation interventions in diabetes. Our analysis includes equal numbers of studies reporting positive and negative effect estimates, which reduces the likelihood of publication bias. The statistical power of the meta-analysis is limited by the small number of trials published to date and a relatively small number of participants in the published trials. Limited statistical power may partially explain the lack of significant findings in the pooled analysis. There are too few trials to draw conclusions about the types of intervention, and differences between type 1 and type 2 diabetes. The extent of heterogeneity in interventions, and intervention and comparator groups, also limited our ability to draw conclusions based on our findings. Most of the included trials provided incomplete information on randomisation, allocation concealment and blinding of participants and personnel which may potentially introduce bias at the level of individual trials.
This review does not include trials in which smoking cessation was a part of a more extensive complex intervention and in which only a proportion of patients had diabetes and smoked at baseline. This limited the number of trials to be reviewed and the size of reviewed population, but allowed us to measure specifically the effect of smoking cessation by reducing the extent of performance bias and detection bias arising from multiple interventions and multiple measurements.
Some studies suggest that smokers with diabetes may be more motivated to stop smoking, than the general smoker population 27 and more likely to stop smoking after hospitalisation compared with patients without diabetes. 28 There is no evidence from our review that, if such motivation is present, it translates into improved outcomes. In other high-risk patient groups, for example, chronic obstructive pulmonary disease 29 and cardiovascular disease, 30 higher point estimates of the effect of intervention on smoking cessation are reported with most trials extending to 12-month follow-up.
An earlier, narrative review has examined the issues associated with smoking cessation in diabetes and identified some of the reasons why evaluation of smoking cessation interventions in this group may have been dealt with cautiously. 8 The datasheets for most recommended first-line smoking cessation medications 31 caution against their use in diabetes. 8 32 Moreover, studies report that smoking cessation may worsen metabolic profile and glycaemic control 33 34 and lead to weight gain. 35 We have identified four trials not included in the narrative review, two predating the narrative review. 17 19 Further data from randomised trials of interventions evaluating smoking outcomes, weight change and glycaemic control would inform treatment strategies in a population in which smoking cessation is likely to have high absolute benefits. 1 The issue of safety of such treatments is partly addressed in an ongoing trial of varenicline for smoking cessation in diabetes, 24 but the follow-up period of 6 months is likely to be too short to identify sustained effects. Trials assessing combinations of NRT with varenicline or bupropion in addition to non-pharmacological interventions may, in any case, better reflect clinical practice. 31 Despite the potential health benefits of smoking cessation in diabetes, there has been limited work on developing and evaluating tailored interventions to support smoking cessation in these patients. From a health services perspective, it would be important to know whether a tailored intervention is more effective in this patient group than providing the same management as for the general population. Given the high burden of self-management required of people with diabetes, it is possible that integrating an intervention with routine care may be more effective than managing the problem separately. Further work is needed to explore the role of this approach in clinical care using trial designs with follow-up extending to at least 1 year.
